PMC:4939752 / 41410-41598 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/4939752","sourcedb":"PMC","sourceid":"4939752","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4939752","text":"Ublituximab(LFB-R603, EMAB-6)Phase I GTC Bio therapeutics,LFB BiotechnologiesType ImAb Chimeric; IgG1Glycoengineered Ublituximab, (12 patients of Advanced CLL, ORR 35%) [102] High ADCC","divisions":[{"label":"td","span":{"begin":0,"end":36}},{"label":"td","span":{"begin":38,"end":87}},{"label":"td","span":{"begin":89,"end":118}},{"label":"td","span":{"begin":120,"end":177}}],"tracks":[]}